• The technology described in this briefing is Ocular Response Analyzer (ORA) G3. It can be used to measure corneal hysteresis, a possible risk factor for glaucoma.

  • The innovative aspects are that ORA G3 is currently the only device capable of measuring corneal hysteresis.

  • The intended place in therapy would be when diagnosing and managing suspected glaucoma or monitoring established glaucoma. ORA G3 would be used in addition to standard care, specifically ophthalmic tests including Goldmann applanation tonometry.

  • The main points from the evidence summarised in this briefing are from 5 observational studies, 4 in the US and 1 in Korea, including a total of 635 adults recruited from glaucoma clinics. Results show that lower levels of corneal hysteresis are associated with the development and progression of glaucoma.

  • Key uncertainties around the evidence or technology are whether the published studies are applicable to the NHS, and if corneal hysteresis is indeed a reliable risk factor for glaucoma.

  • The cost of ORA G3 is £11,995 per unit (excluding VAT), plus additional costs for maintenance and consumables. The resource impact would be greater than standard care, but using ORA G3 may provide more long-term savings if measuring corneal hysteresis allows for earlier diagnosis and treatment of glaucoma.